Search research articles
Contact Us
Filters
Showing results (21-30 of 203) with videos related to
Page
of 21
Sort By:
Therapeutic Advances in Neurological Disorders
|
May 26, 2021
Dalfampridine improves slowed processing speed in multiple sclerosis patients with mild motor disability: post hoc analysis of a randomized controlled trial
Carlo Pozzilli, Luca Prosperini, Silvia Tommasin, et al.
Expert Review of Neurotherapeutics
|
May 18, 2022
A systematic review of European regional and national guidelines: a focus on the recommended use of nabiximols in the management of spasticity in multiple sclerosis
Francisco Javier Carod-Artal, Peyman Adjamian, Carlos Vila Silván, et al.
Expert Opinion on Emerging Drugs
|
September 4, 2008
Emerging oral drugs for multiple sclerosis
Claudio Gasperini, Luca Ausili Cefaro, Giovanna Borriello, et al.
Journal of the Neurological Sciences
|
October 22, 2003
Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years
Francesca Bellomi, Carolina Scagnolari, Valentina Tomassini, et al.
Multiple Sclerosis and Related Disorders
|
May 24, 2025
Brain bright spotty lesions and leukodystrophy-like patterns in NMOSD relapse
Alessandro Cruciani, Alessandro Stasolla, Shalom Haggiag, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|
October 10, 2024
Transient vertical diplopia following ibuprofen intake: a case report
Shalom Haggiag, Luca Prosperini, Federico Sadun, et al.
Plos One
|
March 8, 2022
Cost-effectiveness and budget impact analysis of siponimod in the treatment of secondary progressive multiple sclerosis in Italy
Paolo Angelo Cortesi, Ippazio Cosimo Antonazzo, Claudio Gasperini, et al.
Journal of the Neurological Sciences
|
October 25, 2016
Prolonged-release fampridine treatment improved subject-reported impact of multiple sclerosis: Item-level analysis of the MSIS-29
Claudio Gasperini, Raymond Hupperts, Jan Lycke, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|
May 5, 2023
Patient-reported outcome measures in drugs for neurological conditions approved by European Medicines Agency 2017-2022
Oriana Ciani, Michela Meregaglia, Mario Alberto Battaglia, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
April 28, 2022
Shift of multiple sclerosis onset towards older age
Luca Prosperini, Matteo Lucchini, Serena Ruggieri, et al.
Page
of 21
Search research articles
Search
Showing results (21-30 of 203) with videos related to
Sort By:
Page
of 21
Therapeutic Advances in Neurological Disorders
|
May 26, 2021
Dalfampridine improves slowed processing speed in multiple sclerosis patients with mild motor disability: post hoc analysis of a randomized controlled trial
Carlo Pozzilli, Luca Prosperini, Silvia Tommasin, et al.
Expert Review of Neurotherapeutics
|
May 18, 2022
A systematic review of European regional and national guidelines: a focus on the recommended use of nabiximols in the management of spasticity in multiple sclerosis
Francisco Javier Carod-Artal, Peyman Adjamian, Carlos Vila Silván, et al.
Expert Opinion on Emerging Drugs
|
September 4, 2008
Emerging oral drugs for multiple sclerosis
Claudio Gasperini, Luca Ausili Cefaro, Giovanna Borriello, et al.
Journal of the Neurological Sciences
|
October 22, 2003
Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years
Francesca Bellomi, Carolina Scagnolari, Valentina Tomassini, et al.
Multiple Sclerosis and Related Disorders
|
May 24, 2025
Brain bright spotty lesions and leukodystrophy-like patterns in NMOSD relapse
Alessandro Cruciani, Alessandro Stasolla, Shalom Haggiag, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|
October 10, 2024
Transient vertical diplopia following ibuprofen intake: a case report
Shalom Haggiag, Luca Prosperini, Federico Sadun, et al.
Plos One
|
March 8, 2022
Cost-effectiveness and budget impact analysis of siponimod in the treatment of secondary progressive multiple sclerosis in Italy
Paolo Angelo Cortesi, Ippazio Cosimo Antonazzo, Claudio Gasperini, et al.
Journal of the Neurological Sciences
|
October 25, 2016
Prolonged-release fampridine treatment improved subject-reported impact of multiple sclerosis: Item-level analysis of the MSIS-29
Claudio Gasperini, Raymond Hupperts, Jan Lycke, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|
May 5, 2023
Patient-reported outcome measures in drugs for neurological conditions approved by European Medicines Agency 2017-2022
Oriana Ciani, Michela Meregaglia, Mario Alberto Battaglia, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
April 28, 2022
Shift of multiple sclerosis onset towards older age
Luca Prosperini, Matteo Lucchini, Serena Ruggieri, et al.
Page
of 21